KRAS, BRAF V600E Mutations Impact Survival in Colon Cancer

This article originally appeared here.
Share this content:
<i>KRAS</i>, <i>BRAF</i> V600E Mutations Impact Survival in Colon Cancer
KRAS, BRAF V600E Mutations Impact Survival in Colon Cancer

MONDAY, Jan. 18, 2016 (HealthDay News) -- For patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin (FOLFOX), KRAS and BRAF V600E mutations are associated with worse clinical outcome in patients with microsatellite-stable tumors, according to a study published online Jan. 14 in JAMA Oncology.

Julien Taieb, M.D., Ph.D., from the Paris Descartes University, and colleagues examined the prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer. They determined mismatch repair, BRAF V600E, and KRAS exon 2 mutational status in prospectively collected tumor blocks from 2,559 patients enrolled in the PETACC-8 phase III randomized trial, who were randomized to six months of FOLFOX4 or FOLFOX4 plus cetuximab.

The researchers found that 9.9 percent of participants had microsatellite instability (MSI) phenotype, 33.1 percent had KRAS mutation, and 9.0 percent had BRAF V600E mutation. In multivariate analysis, KRAS mutation correlated with shorter disease-free survival (DFS) and overall survival (OS) (hazard ratios, 1.55 and 1.56, respectively), while MSI and BRAF V600E were not prognostic. In subgroup analysis, independent associations for worse clinical outcomes were seen for patients with microsatellite-stable tumors with KRAS (hazard ratios for DFS and OS, 1.64 and 1.71, respectively) and BRAF V600E mutations (hazard ratios for DFS and OS, 1.74 and 1.84, respectively).

"BRAF V600E and KRAS mutations were significantly associated with shorter DFS and OS in patients with microsatellite-stable tumors but not in patients with MSI tumors," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Merck and Sanofi, both of which supported the study and provided study medications.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ancient Gene Protects Elephants From Cancer

Ancient Gene Protects Elephants From Cancer

The LIF6 gene destroys cells with damaged DNA

Reasons for Undergoing Cosmetic Procedures Explored

Reasons for Undergoing Cosmetic Procedures Explored

Psychological and emotional motivations more likely in patients wanting acne scar tx, tattoo removal

DNR Orders Linked to Increased Mortality in Older Adults

DNR Orders Linked to Increased Mortality in Older ...

Early versus late DNR tied to shorter median length of stay in hospitalized adults aged 65 years and older

is free, fast, and customized just for you!




Already a member?

Sign In Now »